Eric Lawitz, MD
Dr. Lawitz is a Medical Director of the Texas Liver Institute and a Clinical Professor of Medicine at University of Texas Health Science Center in San Antonio, Texas. Dr. Lawitz received a B.S. from University of Illinois Chicago and M.D. from Rush Medical College. Dr. Lawitz received his postgraduate training in Gastroenterology/Hepatology at Brooke Army Medical Center and is board certified in the area of Gastroenterology/Hepatology.
- 1999 - Fellowship - Gastroenterology - Brooks Army Medical Center, TX
- 1994 - Internship - Internal Medicine - Brooks Army Medical Center, TX
- 1993 - MD - Medicine - Rush Medical College, Chicago, IL
William Beaumont Clinical Research Award
Cover Feature: Featured on cover of periodical "Hepatitis" 2002 Vol. 4 (2)
Recognition of Investigator-Initiated Research: Recognizing Discover and Innovation in 2001: Milestone Award in Hepatitis C, Dallas, TX; awarded Milestone Award
Lifetime Member: Listed in The National Registry of Who's Who
Research & Grants
1.Lawitz EJ. Diagnosis and management of telaprevir-associated rash. Gastroenterol Hepatol (N Y) 2011 Jul;7(7):469-471.
2.Lawitz EJ, ESTEBAN R, GORDON S, MARCELLIN P, VIERLIN J, ZEUZEM S, POORDAD F, BOPARAI N, BURROUGHS M, ALBRECHT J, BRASS C, BACON B. Utility of historical data compared to lead-in response in predicting sustaned virologic response to non-responders and relapsers to Peginterferon/Ribavirin when re-treated with Boceprevir Peginterferon Alfa-2B/Ribavirin(P/R) Journal of Hepatology 2011;54(1)
Lawitz EJ, JACOBSON I, GODOFSKY E, FOSTER G, FLISIAK R, BENNETT M, RYAN M, HINKLE J, SIMPSON J, McHUTCHISON J, OLDACH D. A phase 2B trial comparing 24 to 48 weeks treatment with Tegobuvir(GS-9190)/PEG/RBV TO 48 weeks treatment with PEG/RBV for chronic genotype-1 HCV Infection Journal of Hepatology 2011;54(1)
Lawitz EJ, Long W, Younossi Z, Kotsev I, Takov D, Tchernev K, Rigney A, Ghalib R, Stoinov S, Balabanska R, Mehra P, Krastev Z. Timing and frequency of depression during HCV-treatment with controlled-release IFNA2B(CR2B) VS pegylated-IFNA2B(PEG2B): Results from Select-2, A randomized open label 72 week comparison in 116 treatment naive patients with Genotype-1 HCV. Journal of Hepatology 2011;54(1)